Literature DB >> 33738541

Liposarcoma in children and young adults: a clinicopathologic and molecular study of 23 cases in one of the largest institutions of China.

Ran Peng1, Nan Li2, Ting Lan3, Huijiao Chen1, Tianhai Du1, Xin He1, Min Chen1, You Xie1, Zhang Zhang1, Wei Zhao1, Hongying Zhang4.   

Abstract

The incidence of pediatric liposarcoma is rare and most published cases lack systematic genetic analyses. We present clinicopathologic and genetic features of 23 liposarcomas aged <22 years. The study cohort comprised 10 males and 13 females (M:F=1:1.3) aged 11-21 years (median 17 years). The tumors predominantly occurred at the extremities (16/23; 69.6%), followed by the head/neck (2/23; 8.7%), chest (2/23; 8.7%), waist (2/23, 8.7%), and retroperitoneum (1/23; 4.3%). The tumor subtypes were sixteen myxoid liposarcoma (ML), one well-differentiated liposarcoma (WDL), two dedifferentiated liposarcoma (DDL), one pleomorphic liposarcoma (PL), and three myxoid pleomorphic liposarcoma (MPL) cases. Fluorescence in situ hybridization analysis identified MDM2/CDK4 amplification in all WDL/DDL cases (3/3; 100%) and DDIT3 rearrangement in all ML cases (13/13; 100%). Whole-exome sequencing indicated that one PL case and one MPL case exhibited RB1 loss. The two tested MPL cases had TP53 mutation and one of them harbored a TP53 germline mutation. Follow-up information was available for 20 patients (20/23; 87.0%) with a median follow-up duration of 42.5 months (range, 13-120 months). Three patients exhibited tumor progression (3/20;15.0%). Seventeen patients (17/20; 85.0%) survived with no evidence of disease. One MPL case (1/20; 5.0%) died of the disease. In conclusion, despite some overlaps, the occurrence, distribution of subtype, and prognosis of liposarcoma are overall different in children and adults. Most MLs and ALT/WDL/DDLs showed similar genetic aberrations with adult counterparts. Molecular features of MPL overlapped with those of conventional PL. The genetic characteristics including Tp53 status of MPL need further investigation.

Entities:  

Keywords:  Liposarcoma; Li–Fraumeni syndrome; Molecular analysis; Pediatric sarcoma; Prognosis

Year:  2021        PMID: 33738541     DOI: 10.1007/s00428-021-03076-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  55 in total

1.  A novel sclerosing atypical lipomatous tumor/well-differentiated liposarcoma in a 7-year-old girl: report of a case with molecular confirmation.

Authors:  Ran Peng; Huijiao Chen; Xuantao Yang; Xianliang Zhang; Zhang Zhang; Xin He; Hongying Zhang
Journal:  Hum Pathol       Date:  2017-07-11       Impact factor: 3.466

Review 2.  Adipose and myxoid tumors of childhood and adolescence.

Authors:  Cheryl M Coffin; Rita Alaggio
Journal:  Pediatr Dev Pathol       Date:  2012

3.  Childhood liposarcoma: a single-institutional twenty-year experience.

Authors:  A Ferrari; M Casanova; F Spreafico; R Luksch; M Terenziani; G Cefalo; M Massimino; L Gandola; P Navarria; F Fossati-Bellani
Journal:  Pediatr Hematol Oncol       Date:  1999 Sep-Oct       Impact factor: 1.969

Review 4.  Adipocytic tumors in Children: A contemporary review.

Authors:  Juan Putra; Alyaa Al-Ibraheemi
Journal:  Semin Diagn Pathol       Date:  2019-02-28       Impact factor: 3.464

5.  Liposarcoma in children and young adults: a multi-institutional experience.

Authors:  Winston W Huh; Carrie Yuen; Mark Munsell; Andrea Hayes-Jordan; Alexander J Lazar; Shreyaskumar Patel; Wei-Lien Wang; Nadia Barahmani; M Fatih Okcu; John Hicks; Larisa Debelenko; Sheri L Spunt
Journal:  Pediatr Blood Cancer       Date:  2011-03-10       Impact factor: 3.167

6.  Liposarcoma in patients younger than or equal to 22 years of age.

Authors:  M P La Quaglia; S A Spiro; F Ghavimi; S I Hajdu; P Meyers; P R Exelby
Journal:  Cancer       Date:  1993-11-15       Impact factor: 6.860

7.  Atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma in patients aged ≤ 40 years: a study of 116 patients.

Authors:  Rebecca Waters; Andrew Horvai; Patricia Greipp; Ivy John; Elizabeth G Demicco; Brendan C Dickson; Munir R Tanas; Brandon T Larsen; Nasir Ud Din; David H Creytens; Armita Bahrami; Leona A Doyle; Vickie Y Jo; Alyaa Al-Ibraheemi; Khin Thway; Sarah M Jenkins; Brittany Siontis; Andrew Folpe; Karen Fritchie
Journal:  Histopathology       Date:  2019-10-13       Impact factor: 5.087

8.  Liposarcoma occurring in children. An analysis of 17 cases and review of the literature.

Authors:  B M Shmookler; F M Enzinger
Journal:  Cancer       Date:  1983-08-01       Impact factor: 6.860

9.  Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age.

Authors:  Rita Alaggio; Cheryl M Coffin; Sharon W Weiss; Julia A Bridge; Josephine Issakov; Andre M Oliveira; Andrew L Folpe
Journal:  Am J Surg Pathol       Date:  2009-05       Impact factor: 6.394

10.  Prognostic factors and survival in pediatric and adolescent liposarcoma.

Authors:  Eric J Stanelle; Emily R Christison-Lagay; Emma L Sidebotham; Samuel Singer; Cristina R Antonescu; Paul A Meyers; Michael P La Quaglia
Journal:  Sarcoma       Date:  2012-09-05
View more
  3 in total

1.  Well-differentiated lipomatous neoplasms with p53 alterations: a clinicopathological and molecular study of eight cases with features of atypical pleomorphic lipomatous tumour.

Authors:  Phoebe M Hammer; Christian A Kunder; Brooke E Howitt; Gregory W Charville
Journal:  Histopathology       Date:  2022-01-05       Impact factor: 5.087

Review 2.  Update of Pediatric Lipomatous Lesions: A Clinicopathological, Immunohistochemical and Molecular Overview.

Authors:  Eline Ameloot; Fleur Cordier; Jo Van Dorpe; David Creytens
Journal:  J Clin Med       Date:  2022-03-31       Impact factor: 4.241

3.  Primary intrathoracic liposarcomas: A clinicopathologic and molecular study of 43 cases in one of the largest medical centers of China.

Authors:  You Xie; Wenyi Jing; Wei Zhao; Ran Peng; Min Chen; Ting Lan; Heng Peng; Xin He; Huijiao Chen; Zhang Zhang; Hongying Zhang
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.